The University of Hong Kong (HKU) announces its successful participation in the 50th International Exhibition of Inventions of Geneva, held from 9 to 13 April 2025. HKU achieved outstanding results, winning a total of 34 awards, 12 of which were from the School of Clinical Medicine. This included 4 Gold with Jury Congratulations, 4 Golds, 3 Silvers and 1 Bronze medal from the School of Clinical Medicine.

The International Exhibition of Inventions of Geneva is the largest global annual exhibition devoted exclusively to inventions, serving as a vital platform for inventors, researchers, and industry leaders from around the world. This year’s exhibition featured over 1,000 inventions from over 35 countries and regions. Notably, 4 projects from the School of Clinical Medicine won the Gold Medal with Jury Congratulations, including: 

1. A Multimodal Medical Screening and Disease Monitoring Platform to Serve Healthcare Professionals, Patients, and Families in Primary Health Settings with Clinical Standard Readout, Environmental Versatility, and Accessibility
   
   The project aims to provide healthcare professionals, patients, and families with a portable Electrical Impedance Tomography (EIT) system for the early detection and monitoring of vital organs such as the lung, liver, kidney, heart, and brain. Designed for use in primary healthcare settings like clinics, community centers, and homes, this non-invasive technology utilizes advanced microelectronics to measure impedance distribution in organs and generates clinically standard readouts through AI-enabled processing. The EIT system is validated by clinical professionals, offering a unique solution for disease detection and monitoring in community, clinic, and home environments.
    
   It is led by Prof Desmond YAP from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, Dr Russell W. CHAN and Dr Eddie C. WONG
   
   
2. Circulating Thrombospondin-2 (TSP2) - A Novel Fibrosis Biomarker for Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
   
   The project focuses on using circulating thrombospondin-2 levels as a simple and non-invasive blood biomarker to predict the presence and progression of advanced liver fibrosis. This biomarker is significant for identifying critical stages of steatotic liver disease, which can influence disease progression in patients with type 2 diabetes and related metabolic disorders.  
   
   It is led by Dr Chi-Ho LEE, Prof Karen Siu-Ling LAM and Prof Aimin XU from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine.
   
   
3. Compositions and Methods of Gamma-delta T Cell Extracellular Vesicle-based Tumor Vaccines
   
   The project focuses on utilizing extracellular vesicles derived from γδ-T cells as a versatile platform for cancer vaccine development. This approach enhances immune activation and exerts antitumor effects, offering a scalable and ready-to-use solution for various cancers. The technology highlights include the use of γδ-T-EVs to deliver tumor antigens, stimulate immune responses, and directly eliminate tumor cells, ensuring improved safety, effectiveness, and broad applicability in cancer treatment.  
   
   It is led by Prof Wenwei TU, Dr Yinping LIU and Dr Xiwei WANG from the Department of Paediatrics & Adolescent Medicine, School of Clinical Medicine, LKS Faculty of Medicine.
   
   
4. Methods to Prepare Vdelta2-T Cells Derived Exosomes for Treatment of Epstein-Barr Virus-Associated Cancers
   
   The project focuses on developing techniques to produce exosomes from Vdelta2-T cells (Vδ2-T-Exos) aimed at treating EBV-associated cancers. These exosomes selectively target and kill tumor cells while enhancing T-cell antitumor immunity, providing a stable, scalable, and safer cancer therapy option. The innovation introduces Vδ2-T-Exos, which not only induces apoptosis in EBV-related tumor cells but also bolsters T cell-mediated immunity, offering high bioavailability and low side effects, thus presenting a promising cell-free immunotherapy for effective treatment of EBV-related cancer  
   
   It is led by Prof Wenwei TU, Dr Yinping LIU and Dr Xiwei WANG from the Department of Paediatrics & Adolescent Medicine, School of Clinical Medicine, LKS Faculty of Medicine.

Warmest congratulations to all awardees from our School. Click here for a complete list of HKU’s inventions participated in the event and further details.